Scan here for your digital symposium programme
Unique solutions for customised results
Discover the Merz Aesthetics product line, a full range of aesthetic options that deliver individual solutions and exceptional results. To fi nd out more, please visit
www.merzaesthetics.eu/en/qr or meet us at AMWC 2012 (booth H3).
Bocouture®
4 units/0.1 ml powder for solution for injection. Active substance:
Botulinum toxin type A (150 kD), free from complexing proteins. Prescription-only medicine! Qualitative and quantitative composition: One vial contains: 50 LD50 units of Botulinum toxin type A (150 kD), free from complexing proteins, Human albumin, Sucrose. Therapeutic indications: For temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at frown (glabellar frown lines) in adults below 65 years when the severity of these lines has an important psychological impact for the patient. Contraindications: Hypersensitivity to Botulinum neurotoxin type A or to any of the excipients, generalised disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome). Presence of infection or infl ammation at the proposed injection site. Bocouture® used during pregnancy unless clearly necessary. The use of Bocouture®
should not be during
lactation cannot be recommended. Undesirable effects: Usually, undesirable effects are observed within the fi rst week after treatment and are temporary in nature. Localised pain, tenderness, itching, swelling and/or haematoma can occur in conjunction with the injection. Temporary vasovagal reactions associated with
pre-injection anxiety, such as syncope, circulatory problems, nausea or tinnitus, may occur. Common ( ≥ 1/100, < 1/10): headache, muscle disorders (elevation of eyebrow), sensation of heaviness. Uncommon (≥ 1/1,000, < 1/100): bronchitis, nasopharyngitis, infl uenza, depression, insomnia, facial paresis (brow ptosis), vasovagal syncope, eyelid oedema, eyelid ptosis, blurred vision, tinnitus, nausea, pruritus, skin nodule, muscle twitching, muscle cramps, injection site reactions (bruising, pruritus), tenderness, infl uenza like illness, fatigue (tiredness). For adverse reactions reported with the comparator product containing conventional Botulinum toxin type A complex of equal potency see Summary of Product Characteristics. General: In rare cases, localised allergic reactions, such as swelling, oedema, erythema, pruritus or rash, have been r eported after treating vertical lines between the eyebrows (glabellar frown lines) and other indications. For undesirable effects when treating other indications with Botulinum toxins see Summary of Product Characteristics. Merz Pharmaceuticals GmbH, 60048 Frankfurt/Main, Germany, Phone: ++49-69/1503-1. Date of revision of the text: July 2010 (in Germany). Further information is provided in the Summary of Product Characteristics and in the Package Leafl et.
SmPC and IFU are available on the booth. Radiesse (CE0086) and Belotero (CE0120) are medical devices.
SATELLITE SYMPOSIUM at AMWC 2012
Saturday, March 31st 2 pm – 4 pm, Room Nij inski
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112